Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints | Zendy

Laura Kovanda | Zendy; Rūta Petraitienė | Zendy; Vidmantas Petraitis | Zendy; Thomas J. Walsh | Zendy; Amit Desai | Zendy; Peter L. Bonate | Zendy; William Hope | Zendy

Open Access

Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints

Author(s) -

Laura Kovanda,

Rūta Petraitienė,

Vidmantas Petraitis,

Thomas J. Walsh,

Amit Desai,

Peter L. Bonate,

William Hope

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkw098

Subject(s) - pharmacodynamics , voriconazole , population , medicine , aspergillosis , clinical endpoint , pharmacology , dosing , pharmacokinetics , area under the curve , dose , clinical trial , gastroenterology , immunology , antifungal , environmental health , dermatology

Isavuconazole, a novel triazole antifungal agent, has broad-spectrum activity against Aspergillus spp. and other pathogenic fungi. The isavuconazole exposure-response relationship in experimental invasive pulmonary aspergillosis using galactomannan index (GMI) suppression as a marker of disease clearance was explored.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research